Management of protease inhibitor-associated diarrhea

Clinical Infectious Diseases

Volumn 30, Issue 6, 2000, Pages 908-914

  Sherman, D S ^a   Fish, D N ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; CROFELEMER; ISPAGULA; LOPERAMIDE; PANCRELIPASE; PROTEINASE INHIBITOR;

ARTICLE; BRAN; DIARRHEA; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIFESTYLE; MALNUTRITION; MORTALITY; OAT; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT PLANNING; WEIGHT REDUCTION;

ANTIDIARRHEALS; CLINICAL TRIALS; DIARRHEA; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 0034464855     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313826     Document Type: Article

References (30)

1. Diarrhea in patients with the acquired immunodeficiency syndrome
2. Enteric infections and diarrhea in human immunodeficiency virus-infected persons
3. Revision of the CDC surveillance case definition of acquired immunodeficiency syndrome
4. Diarrhea and AIDS in the era of highly active antiretroviral therapy
5. Infection with the human immunodeficiency virus: Clinical manifestations and their relationship to immune deficiency
6. Diarrhea and quality of life in ambulatory HIV-infected patients
7. The incidence and severity of diarrhea in HIV+ patients from a large, urban medical center who have taken nelfinavir in the past twelve months
8. Protease inhibitors for the treatment of human immunodeficiency virus infection
9. HIV-protease inhibitors
10. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: Results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus
11. Low rate of nelfinavir discontinuation in a clinical population
12. The patient's perspective on life with antiretroviral treatment: Results of an 887-person survey
13. Obstacles in treatment adherence: Patient reasons
14. Compliance with zidovudine in patients infected with human immunodeficiency virus, type 1: A crosssectional study in a municipal hospital clinic
15. Oat bran tablets are an effective natural supplement for the management of protease inhibitor-induced diarrhea
16. Nelfinavir-associated diarrhea is manageable with nonprescription medications
17. Psyllium husk fiber bars are efficacious in the treatment of protease inhibitor (PI)-induced diarrhea
18. The treatment of nelfinavir-induced diarrhea
19. The role of calcium supplements in the treatment of nelfinavir induced diarrhea
20. A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion
21. SP-303: A new treatment for AIDS-associated diarrhea
22. The success of using pancreatic enzymes in controlling protease inhibitor induced diarrhea in HIV+ patients
23. A double-blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Mexico and Jamaica
24. Symptom management in HIV-infected patients
25. Pathophysiology of HIV-associated diarrhea